Ignite Creation Date:
2025-12-25 @ 1:04 AM
Ignite Modification Date:
2026-01-01 @ 11:49 PM
Study NCT ID:
NCT04906993
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-09
First Post:
2021-05-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-23
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-26
First Submit QC Date:
None
Study First Post Date:
2021-05-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-08
Last Update Post Date:
2025-09-09
Last Update Post Date Type:
ESTIMATED